NPS Pharmaceuticals 8-K 2007
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On October 3, 2007, NPS Pharmaceuticals, Inc. issued a press release announcing an increase in the purchase price of its outstanding 3.0% convertible notes due 2008 (the Notes) to $987.50 per $1,000.00 principal amount of the Notes, plus accrued and unpaid interest up to, but not including, the date of payment for the Notes accepted for payment, and an extension of the tender offer until midnight, New York City time, on October 17, 2007. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.